FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196503620> ?p ?o ?g. }

• W3196503620 abstract "Background: Marginal resection frequently occurred in hepatectomy for hepatocellular carcinoma (HCC), which led to increased local recurrence, especially among patients with microvascular invasion (MVI). Stereotactic body radiotherapy (SBRT) shows effective in tumor controlling, while limited research reported the efficacy of SBRT as adjuvant setting for HCC after surgery. We hypothesized existence of residual tumor cells or foci in unsafe margin parenchyma caused local recurrence in HCC patients with MVI, and SBRT might be a solution to resolve the problem. This study aimed to investigate the efficacy of SBRT targeting on the susceptible area with residue MVI as adjuvant setting for HCC patients.Methods: This was a single center, randomized controlled trial conducted in Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Participants with HCC and MVI receiving marginal resection were randomly assigned to postoperative adjuvant SBRT group or surgery alone (SA) group. SBRT was delivered by the CyberKnife® system (Accuracy Inc., Sunnyvale) with marker tracking devices. Patients in SBRT group received SBRT targeting on the resection marginal parenchyma where MVI most likely occurred one month after surgery. The disease-free survival (DFS) and overall survival (OS) were compared between the groups and the adverse events (AE) in the SBRT group were monitored. This trial was registered with ClinicalTrials.gov, NCT04891874.Findings: A total of 76 participants were enrolled from August 1, 2015 to December 31, 2016, with 38 in each group. The 1-, 3-, and 5-year DFS rates were 92.1%, 65.8%, and 56.1% in the SBRT group, versus 76.3%, 36.8%, and 26.3% in the SA group, respectively (p=0.005). The 1-, 3-, and 5-year OS rates were 100%, 89.5%, and 75.0% in the SBRT group, versus 100.0%, 68.4%, and 53.7% in the SA group, respectively (p=0.053). The total dose of SBRT for each participant was 35Gy and the biological effective dose (BED) is 59.5 Gy. The overall incidence of radiotherapy related AE was 31.6% (12/38), and no grade 3 or higher grade AE developed. Fatigue was the most frequent AE.Interpretation: SBRT on resection marginal parenchyma provides a safe therapeutic modality of adjuvant setting in MVI-positive HCC participants without satisfying resection margin. It prevents local recurrence and improves disease-free survival. Further evidence is necessary to evaluate its long-term survival outcome.Clinical Trial Registration Details: This trial was registered with ClinicalTrials.gov, NCT04891874.Funding Information: This research has received funding from the ‘Clinical science and technology innovation project of Shenkang Hospital Development Center’ (SHDC12020104).Declaration of Interests: The authors disclose no conflicts.Ethics Approval Statement: Detailed information of the clinical protocol was explained to every participants and written informed consent were collected before randomization. This trial was approved by the Institutional Ethics Committee of Shanghai Eastern Hepatobiliary Surgery Hospital. The study protocol conformed to the principles of Declaration of Helsinki (1983)." @default.
• W3196503620 created "2021-09-13" @default.
• W3196503620 creator A5020733153 @default.
• W3196503620 creator A5023214008 @default.
• W3196503620 creator A5043300709 @default.
• W3196503620 creator A5044685285 @default.
• W3196503620 creator A5056252246 @default.
• W3196503620 creator A5069414708 @default.
• W3196503620 creator A5069701729 @default.
• W3196503620 creator A5079289072 @default.
• W3196503620 creator A5083300951 @default.
• W3196503620 date "2021-01-01" @default.
• W3196503620 modified "2023-09-25" @default.
• W3196503620 title "Adjuvant Stereotactic Body Radiotherapy After Marginal Resection for Hepatocellular Carcinoma With Micro-Vascular Invasion: A Randomized Controlled Trial" @default.
• W3196503620 cites W1990652990 @default.
• W3196503620 cites W2044925422 @default.
• W3196503620 cites W2084112669 @default.
• W3196503620 cites W2092163967 @default.
• W3196503620 cites W2096998881 @default.
• W3196503620 cites W2115991409 @default.
• W3196503620 cites W2130387175 @default.
• W3196503620 cites W2218030309 @default.
• W3196503620 cites W2552389495 @default.
• W3196503620 cites W2606367731 @default.
• W3196503620 cites W2734461272 @default.
• W3196503620 cites W2752254033 @default.
• W3196503620 cites W2787942673 @default.
• W3196503620 cites W2800984355 @default.
• W3196503620 cites W2802010540 @default.
• W3196503620 cites W2889646458 @default.
• W3196503620 cites W2896730640 @default.
• W3196503620 cites W2915848278 @default.
• W3196503620 cites W2921958567 @default.
• W3196503620 cites W2922707684 @default.
• W3196503620 cites W2953129364 @default.
• W3196503620 cites W2964948979 @default.
• W3196503620 cites W2966472134 @default.
• W3196503620 cites W3029711266 @default.
• W3196503620 cites W4211183069 @default.
• W3196503620 doi "https://doi.org/10.2139/ssrn.3912534" @default.
• W3196503620 hasPublicationYear "2021" @default.
• W3196503620 type Work @default.
• W3196503620 sameAs 3196503620 @default.
• W3196503620 citedByCount "0" @default.
• W3196503620 crossrefType "journal-article" @default.
• W3196503620 hasAuthorship W3196503620A5020733153 @default.
• W3196503620 hasAuthorship W3196503620A5023214008 @default.
• W3196503620 hasAuthorship W3196503620A5043300709 @default.
• W3196503620 hasAuthorship W3196503620A5044685285 @default.
• W3196503620 hasAuthorship W3196503620A5056252246 @default.
• W3196503620 hasAuthorship W3196503620A5069414708 @default.
• W3196503620 hasAuthorship W3196503620A5069701729 @default.
• W3196503620 hasAuthorship W3196503620A5079289072 @default.
• W3196503620 hasAuthorship W3196503620A5083300951 @default.
• W3196503620 hasConcept C126322002 @default.
• W3196503620 hasConcept C126838900 @default.
• W3196503620 hasConcept C141071460 @default.
• W3196503620 hasConcept C143998085 @default.
• W3196503620 hasConcept C159110652 @default.
• W3196503620 hasConcept C168563851 @default.
• W3196503620 hasConcept C2777863537 @default.
• W3196503620 hasConcept C2778019345 @default.
• W3196503620 hasConcept C509974204 @default.
• W3196503620 hasConcept C71924100 @default.
• W3196503620 hasConceptScore W3196503620C126322002 @default.
• W3196503620 hasConceptScore W3196503620C126838900 @default.
• W3196503620 hasConceptScore W3196503620C141071460 @default.
• W3196503620 hasConceptScore W3196503620C143998085 @default.
• W3196503620 hasConceptScore W3196503620C159110652 @default.
• W3196503620 hasConceptScore W3196503620C168563851 @default.
• W3196503620 hasConceptScore W3196503620C2777863537 @default.
• W3196503620 hasConceptScore W3196503620C2778019345 @default.
• W3196503620 hasConceptScore W3196503620C509974204 @default.
• W3196503620 hasConceptScore W3196503620C71924100 @default.
• W3196503620 hasLocation W31965036201 @default.
• W3196503620 hasOpenAccess W3196503620 @default.
• W3196503620 hasPrimaryLocation W31965036201 @default.
• W3196503620 hasRelatedWork W2002120878 @default.
• W3196503620 hasRelatedWork W2047967234 @default.
• W3196503620 hasRelatedWork W2118496982 @default.
• W3196503620 hasRelatedWork W2330632952 @default.
• W3196503620 hasRelatedWork W2439875401 @default.
• W3196503620 hasRelatedWork W2528027086 @default.
• W3196503620 hasRelatedWork W2613018095 @default.
• W3196503620 hasRelatedWork W3013078511 @default.
• W3196503620 hasRelatedWork W3091367366 @default.
• W3196503620 hasRelatedWork W3205405682 @default.
• W3196503620 isParatext "false" @default.
• W3196503620 isRetracted "false" @default.
• W3196503620 magId "3196503620" @default.
• W3196503620 workType "article" @default.